EZH2 regulates the malignancy of human glioblastoma cells via modulation of Twist mRNA stability

Xuan Zhai,Lu-Sheng Li,Yu-Dong Zhou,Wen-Yuan Ji,Hui Chen,Han Xiao,Ping Liang,Lu-sheng Li,Yu-dong Zhou,Wen-yuan Ji
DOI: https://doi.org/10.1016/j.ejphar.2021.174177
IF: 5.195
2021-08-01
European Journal of Pharmacology
Abstract:<p>Glioblastoma multiforme (GBM) is a lethal primary brain tumor with poor survival lifespan and dismal outcome. However, the effects and mechanisms of epigenetic factors on the development of GBM were still not well illustrated. We found that expression of enhancer of zeste homolog 2 (EZH2), which can catalyze histone H3K27me3 to modulate gene expression, was increased in GBM cells. Knockdown of EZH2 can suppress proliferation and migration, while increase temozolomide (TMZ) sensitivity, of GBM cells. Further, knockdown of EZH2 or its specific inhibitor GSK126 can decrease expression of Twist, while over expression of Twist can reverse si-EZH2-suppressed malignancy of GBM cells. Mechanistically, EZH2 can positively regulate mRNA stability of <em>Twist1</em> mRNA. Further, miR-206, which can bind with 3'UTR of <em>Twist1</em> mRNA, was involved in EZH2-regulated mRNA stability of <em>Twist1</em>. Collectively, our data suggest that EZH2 might be a potential target for GBM treatment. Further, miR-206/Twist axis is involved in EZH2-regulated malignancy of GBM cells.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the role and mechanism of Enhancer of zeste homolog 2 (EZH2) in the progression of glioblastoma multiforme (GBM). Specifically, the researchers focused on how EZH2 affects the malignant behaviors of GBM cells, including proliferation, migration, and changes in sensitivity to the chemotherapeutic drug temozolomide (TMZ), by regulating the stability of Twist mRNA. ### Research Background - Glioblastoma multiforme (GBM) is a deadly primary brain tumor with poor survival rates and prognoses. - The influence of epigenetic factors on GBM development has not been fully elucidated. - EZH2 is an enzyme capable of catalyzing histone H3K27 trimethylation (H3K27me3) to regulate gene expression, and it exhibits a tumor - promoting effect in various cancers. ### Research Objectives - To investigate the expression of EZH2 in GBM cells. - To analyze the effects of EZH2 on GBM cell proliferation, migration, and TMZ sensitivity. - To reveal the mechanism by which EZH2 affects GBM cell malignancy by regulating Twist mRNA stability. ### Main Findings - **Up - regulation of EZH2 expression**: The study found that the expression of EZH2 in GBM cells was significantly higher than that in normal human astrocytes. - **Functions of EZH2**: - Knockdown of EZH2 can inhibit the proliferation and migration of GBM cells and increase their sensitivity to TMZ. - The specific inhibitor of EZH2, GSK126, can also produce similar effects. - **Regulation of Twist**: - Knockdown of EZH2 or use of GSK126 can reduce Twist expression. - Over - expression of Twist can reverse the inhibitory effect of EZH2 knockdown on GBM cell malignancy. - **Mechanism research**: - EZH2 affects its expression by positively regulating the stability of Twist1 mRNA. - miR - 206 participates in the EZH2 - regulated Twist1 mRNA stability by binding to the 3' untranslated region (3'UTR) of Twist1 mRNA. ### Conclusions - EZH2 is up - regulated in GBM cells and promotes the malignant behaviors of GBM cells by regulating the stability of Twist mRNA. - The miR - 206/Twist axis plays an important role in the EZH2 - regulated malignant behaviors of GBM cells. - Targeted inhibition of EZH2 may be a potential strategy for the treatment of GBM. Through these findings, the researchers have provided a theoretical basis for further development of treatment strategies targeting EZH2.